Loading the session
Loading the session
Loading instrument
$10.70
−1.56%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +19.6% (SPY −1.6%, XLK −12.6%). 3 months: +38.5% (SPY −0.4%, XLK −5.1%). 1 year: −4.0% (SPY +13.6%, XLK +20.1%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CERT, SPY and XLK · as of 4 Nov 2026
25.7M shares were sold short at the 15 Oct 2026 settlement, 16.8% of the 152.5M shares outstanding; covering them would take 8.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Closed at $11.09 on 4 Nov 2026: 5.5% below the 52-week high of $11.73 (28 Oct 2026) and 149.2% above the low of $4.45 (15 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $11.09 was 20.8% above its 50-day average ($9.18) and 52.2% above its 200-day average ($7.29). It has closed above the 200-day for 72 sessions, since 27 Jul 2026. The 50-day average crossed above the 200-day on 26 Aug 2026, 49 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
November 7, 2025
−23.07%April 11, 2025
+22.84%November 7, 2022
+19.58%